Company: NUTR
Filing Date: 2025-03-25
Form Type: CORRESP
Source: 0001641172-25-000449
Chunk: 287

Company: NUSATRIP Inc
Filing Date: 2025-03-25
Form: CORRESP
Chunk 287
---
us as an “issuer free writing prospectus,” as defined in Rule 433, and have complied and will comply with the requirements of Rule 433 applicable to any Permitted Free Writing Prospectus, including timely Commission filing where required, legending and record keeping.

6. Consideration; Payment of Expenses.

(a) In consideration of the services to be provided for hereunder, the Company shall pay to the Underwriters or their respective designees their pro rata portion (based on the Securities purchased) of the following compensation with respect to the Securities which they are offering:

(i) an underwriting discount equal to seven percent (7.0%) of the aggregate gross proceeds raised in the Offering;

(ii) a non-accountable expense allowance of one percent (1.0%) of the gross proceeds of the Offering;

(iii) an accountable expense allowance of up to $80,000.00, including, among other things, all reasonable fees and expenses of the Underwriters’ outside legal counsel; any reasonable costs and expenses incurred in conducting background checks of the Company’s officers and directors by a background search firm acceptable to the Underwriters; and the costs associated with bound volumes and mementos in such quantities as the Underwriters may reasonably request (the “Accountable Out-of-Pocket Expenses”). The Company has advanced an amount of [$30,000.00] (the “ Advances”) to the Representative in anticipation of any Accountable Out-of-Pocket Expenses to be incurred by the Underwriters. Any expense item over US$5,000 incurred by the Representative shall require prior written or email approval of the Company. The Representative shall promptly return to the Company the Advances against the Accountable Out-of-Pocket Expenses, to the extent that such Accountable Out-of-Pocket Expenses are not actually incurred in accordance with FINRA Rule 5110(g)(4)(A).

(iv) non-redeemable warrants for the Representative to purchase an amount equal to seven percent (7%) of the Shares sold in this Offering (including the Option Shares), substantially in the form and content attached hereto as Annex V, which shall be non-callable and non-cancelable, are due and exercisable upon the closing of this Offering for nominal consideration, and have a five (5) year term starting from the date of the commencement of sales of this Offering, and a cashless exercise feature (the “ Representative’s Warrants”). Such Representative’s Warrants are exercisable at a price of 125% of the public offering price of the Shares offered pursuant